You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
15 November 2024
Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
27 September 2024
FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
6 August 2024
Formycon AG increases its outlook for the 2024 fiscal year
26 July 2024
Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
28 June 2024
FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
12 April 2024
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
